RxDoctor Payments Data

Jessica Jairala Bermudez, PA

Physician Assistant · Miami, FLNPI 1548603756

Payments from drug & device makers

$6,488in general payments, 2019–2025

Across 300 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$624
  • Janssen Scientific Affairs, LLC$268
  • Intercept Pharmaceuticals, Inc.$262
  • Lilly USA, LLC$256
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,18995%
  • Education$2995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,488 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$42,497
Medicare patients
292
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase20$58,625
ClenpiqSod Picosulf/Mag Ox/Citric Ac109$18,713
LinzessLinaclotide13$12,437
Dexlansoprazole DrDexlansoprazole18$5,634
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates59$3,893
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,956
Omeprazole103$1,598
CholestyramineCholestyramine (With Sugar)16$1,584
Famotidine83$1,508
Sucralfate27$1,266
Pantoprazole Sodium106$1,157
Rabeprazole Sodium26$934
Dicyclomine Hcl22$527
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$258
Hydrocortisone12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,298$71,06133 claims
Ferring Pharmaceuticals Inc.Clenpiq$165$18,713109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →